2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R06-R09
Technology and Procedures, Molecular Testing, Bioinformatics, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

988 Synaptojanin-1 couples clathrin-uncoating to PD-1/LAG-3 recycling and regulates T-cell antitumor immunity

Pavan Reddy, MD, Yaping Sun, MD, PhD.2, Akira Yamamoto, MD, PhD.3, Laure Maneix, PhD4, Ana Santibanez, N/A5, Yuichi Sumii, MD, PhD.6, Takashi Ikeda, MD, PhD.7, Tyler Leach, N/A8, Yui Yamamoto, MD, PhD.9, Neelam Prakash Bodhale, PhD10, Meng-Chih Wu, N/A11, Lihong Xu, N/A12, Victoria Ontiveros, N/A13, Caroline White14, Dongchang Zhao, MD, PhD.15, Jason Kirk16
1 Baylor College of Medicine, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Baylor College of Medicine, Houston, Texas, United States
8 Baylor College of Medicine, Houston, Texas, United States
9 Baylor College of Medicine, Houston, Texas, United States
10 Baylor College of Medicine, Houston, Texas, United States
11 Baylor College of Medicine, Houston, Texas, United States
12 Baylor College of Medicine, Houston, Texas, United States
13 Baylor College of Medicine, Houston, Texas, United States
14 Baylor College of Medicine, Houston, Texas, United States, Baylor College of Medicine, Houston, Texas, United States
15 Baylor College of Medicine, Houston, Texas, United States
16 Baylor College of Medicine, Houston, Texas, United States
Current immune checkpoint inhibitors (ICIs) block PD-1 and LAG-3 after they reach the T-cell surface. Whether T cells actively regulate the abundance of these receptors, and wheather receptor density itself determines the depth of checkpoint signaling, and by what mechanism, has remained unknown. We identified the membrane-trafficking pathway that determines whether internalized PD-1 and LAG-3 recycle to the plasma membrane or undergo lysosomal degradation, estabolishing checkpoint receptor density as a previously unrecognized and druggable regulator of T-cell exhaustion. Synaptojanin-1 (Synj1), a phosphoinositide phosohatase known in neurons for clathrin-uncoating during synaptic vesicle recycling, hydrolyzes PI(4,5)P2 after vesicle scission. We discovered its function in T cells and tested the hypothesis that Synj1 controls checkpoint receptor abundance, anti-lymphoma/tumor immunity, and response to ICIs.  

To determine the physiological role of SYNJ1, we generated T cell-specific Synj1 knockout mice using CRISPR/CAS9 and CD4-CRE system. Synj1 deletion preserved thymic and peripheral T-cell development, TCR signaling, and eraly activation, excluding developmental defects. Across B16 melanoma and MC38 colon carcinoma, Synj1-deficient T cells proliferated more rapidly during the first 24-48 hours (p<0.03) while displaying markedly lower surface PD-1 (54±6% reduction, p<0.02) and LAG-3 (61±4%, p=0.010) despite unchanged transcript levels, demonstrating post-translational regulation of checkpoint receptor abundance.

To distinguish receptor abundance from receptor engagement, we compared genetic reduction of checkpoint receptors with saturating antibody blockade. Synj1-deficient mice suppressed tumor growth without antibody, matching or exceeding anti-PD-1 therapy in wild-type (WT) animals(10×102 vs 13.8×102  /mm3 at day 15, p<0.02). PD-1, LAG-3, and dual blockade each produced additional tomor control, demonstrating additive rather than redundant mechanisms. Survival improved across models, and combined PD-1/LAG-3 blockade yielded 100% survival in MC38-bearing Synj1-deficient mice versus 40% in WT controls (p<0.01), with similar benefit in B16.

Mechanically, Synj1 deficiency increased intratumoral CD4+ and CD8+ effector T cells, raised Teff:Treg and Teff:MDSC ratios (P<0.003), and reduced PD-1+ and LAG-3+ tomor-infiltrating lymphocytes (p=0.0024). Single-cell RNA sequecing demonstrated activation of CD4+, CD8+, NK, dendritic cell, and macrophage programs, increased IFN-γ response, CD155-CD226, CXCL, and TNF signaling, expansion of cytotoxic NK cells, and a 45% reduction in terminally exhausted TOX+TCF- CD8+ cells (p<0.004), along with incresed aotuphagy and endoplasmic reticulum stress response. Tumor burden declined, while residual tumor cells activated apoptosis, ferroptosis, necroptosis and pyroptosis. 

We next defined the trafficking step regulated by Synj1. Synj1 deficiency delayed transferrin recycling two-fold (p<0.002) and reduced Rab11a, VPS53, and DENND1B protein levels by > 50%. In WT T cells, PD-1 colocalized with Rab11a recycling endosomes (Pearson correlation coefficient,  PCC>0.71); Synj1 deletion disrupted this interaction (PCC<0.40), redirected PD-1 to LAMP1+ lysosomes, shortened receptor half-life, increased LC3-associated degradation, restored PD-1 expression with chloroquine, identifying lysosomal degradation as the receptor's fate. Synj1 knockdown reproduced these defects in human Jurkat cells, demonstrating conservation of the pathway. In patients with colorectal adenocarcinoma that received PD-1 therapy, low Synj1 expression was associated with prolonged survival, p<0.015. 

These findings establish that checkpoint receptor density is actively regulated rather than passively determined by gene expression. Synj1 functions as the molecular switch that directs checkpoint receptors toward recycling or lysosomal destruction, thereby controlling the size of the inhibitory receptor pool independently of andibody occupacy. By identifying receptor abundance as a fundamental and druggable determinant of checkpoint signaling, this work reveals an upstream therapeutic strategy that complements current checkpoint blockde.
Yaping Sun, MD, PhD.: No relevant conflicts of interest to declare.